ALXO (STOCKS)
ALX Oncology Holdings Inc. Common Stock
$1.940000
-0.070000 (-3.48%)
Prev close: $2.010000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Jason Lettmann
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $280.10M
- Employees
- 49
- P/E (TTM)
- -1.77
- P/B (TTM)
- 2.04
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $82.55M |
| Depreciation and Amortization | $500.00K |
| Research and Development | $61.83M |
| Other Operating Expenses | $20.22M |
| Operating Income/Loss | -$82.55M |
| Income/Loss From Continuing Operations After Tax | -$80.89M |
| Income/Loss From Continuing Operations Before Tax | -$80.89M |
| Interest Expense, Operating | $1.41M |
| Net Income/Loss | -$80.89M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$80.89M |
| Net Income/Loss Available To Common Stockholders, Basic | -$80.89M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.13 |
| Diluted Earnings Per Share | -$1.13 |
| Basic Average Shares | 173,880,271 |
| Diluted Average Shares | 293,996,487 |
| Assets | $160.82M |
| Current Assets | $143.46M |
| Prepaid Expenses | $658.00K |
| Other Current Assets | $142.80M |
| Noncurrent Assets | $17.36M |
| Fixed Assets | $166.00K |
| Other Non-current Assets | $17.20M |
| Liabilities | $24.63M |
| Current Liabilities | $14.78M |
| Accounts Payable | $3.02M |
| Wages | $2.71M |
| Other Current Liabilities | $9.05M |
| Noncurrent Liabilities | $9.86M |
| Long-term Debt | $10.20M |
| Equity | $136.19M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $136.19M |
| Liabilities And Equity | $160.82M |
| Net Cash Flow From Operating Activities | -$70.78M |
| Net Cash Flow From Operating Activities, Continuing | -$70.78M |
| Net Cash Flow From Investing Activities | -$65.89M |
| Net Cash Flow From Investing Activities, Continuing | -$65.89M |
| Net Cash Flow From Financing Activities | $140.25M |
| Net Cash Flow From Financing Activities, Continuing | $140.25M |
| Net Cash Flow | $3.59M |
| Net Cash Flow, Continuing | $3.59M |
| Comprehensive Income/Loss | -$80.88M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$81.15M |
| Other Comprehensive Income/Loss | -$40.10M |